scholarly journals Molecular Phenotypes of Unifocal, Multifocal, and Diffuse Invasive Breast Carcinomas

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Tibor Tot ◽  
Gyula Pekár ◽  
Syster Hofmeyer ◽  
Maria Gere ◽  
Miklós Tarján ◽  
...  
Keyword(s):  
Lymph Node ◽  
Growth Factor Receptor ◽  
Receptor Expression ◽  
Lymph Node Status ◽  
Her2 Overexpression ◽  
Breast Carcinomas ◽  
Invasive Component ◽  
Invasive Breast Carcinomas ◽  
Molecular Phenotypes ◽  
Invasive Carcinomas

We analyzed the subgross distribution of the invasive component in 875 consecutive cases of breast carcinomas using large-format histology sections and compared the immunophenotype (estrogen and progesterone receptor expression, HER2 overexpression and expression of basal-like markers, CK5/6, CK14, and epidermal growth factor receptor) in unifocal, multifocal, and diffuse tumors. Histology grade and lymph node status were also analyzed. Unifocal invasive carcinomas comprised 58.6% (513/875), multifocal invasive carcinomas 36.5% (319/875), and diffuse invasive carcinomas 4.9% (43/875) of the cases. The proportion of lymph node-positive cases was significantly higher in multifocal and diffuse carcinomas compared to unifocal cancers, but no other statistically significant differences could be verified between these tumor categories. Histological multifocality and diffuse distribution of the invasive tumor component seem to be negative morphologic prognostic parameters in breast carcinomas, independent of the molecular phenotype.

scholarly journals High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas

Cancer ◽  
2002 ◽  
Vol 94 (9) ◽  
pp. 2454-2465 ◽  
Author(s):  
Maria Kouvaraki ◽  
Vassilis G. Gorgoulis ◽  
George Z. Rassidakis ◽  
Petros Liodis ◽  
Christos Markopoulos ◽  
...  
Keyword(s):  
Lymph Node ◽  
High Expression ◽  
Lymph Node Status ◽  
Breast Carcinomas ◽  
Expression Levels ◽  
Node Status ◽  
Invasive Breast Carcinomas

Sentinel Node Status and Tumor Characteristics: A Study of 234 Invasive Breast Carcinomas

2005 ◽  
Vol 129 (1) ◽  
pp. 82-84 ◽  
Author(s):  
Ying Cao ◽  
Gladell P. Paner ◽  
Prabha B. Rajan
Keyword(s):  
Lymph Node ◽  
Tumor Size ◽  
Lymphovascular Invasion ◽  
Frozen Section ◽  
Paraffin Section ◽  
Lymph Node Status ◽  
Axillary Lymph ◽  
Breast Carcinomas ◽  
Node Status ◽  
Size Grade

Abstract Context.—Axillary lymph node status is the most important prognostic factor in patients with breast cancer. Tumor size and lymph node status, the most reliable pathologic bases of the tumor staging system, are practical parameters for estimating survival status. With the advent of lymphatic mapping and sentinel node (SN) identification, there is potential for a more efficient and sensitive evaluation of the axillary lymph node status. Objective.—To correlate SN status with tumor size, grade, and lymphovascular invasion. Design.—We examined 234 patients with unifocal breast carcinomas measuring 25 mm or less as detected by preoperative ultrasound during the period May 1998 through December 2002. Sentinel nodes were examined by frozen section and paraffin section as per protocol. Results.—Of the 234 patients, SN was identified in 221 (94.5%). An average of 1.38 SNs were examined per patient. Seventy-seven of 221 patients were SN positive on paraffin section. Sixty-six (85.7%) of these 77 cases could be correctly diagnosed as positive for metastatic carcinoma on frozen section. Two cases reported as positive on paraffin section were reported as suspicious on frozen section. Logistic regression indicated that tumor size, grade, and lymphovascular invasion were all significantly associated with SN status (P < .001). Conclusions.—Tumor size, grade, and lymphovascular invasion were significantly associated with SN status in unifocal invasive breast carcinoma.

scholarly journals Altered Expression of Three EGFR Posttranslational Regulators MDGI, MIG6, and EIG121 in Invasive Breast Carcinomas

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Didier Meseure ◽  
Kinan Drak Alsibai ◽  
Sophie Vacher ◽  
Rana Hatem ◽  
Andre Nicolas ◽  
...  
Keyword(s):  
Expression Patterns ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Growth Inhibitor ◽  
Receptor Activation ◽  
Mrna Levels ◽  
Breast Carcinomas ◽  
Rt Pcr ◽  
Altered Expression ◽  
Invasive Breast Carcinomas

Epidermal growth factor receptor (EGFR) signalling is a highly regulated process with a tight balance between receptor activation and inactivation in invasive breast carcinomas (IBCs) particularly in triple-negative carcinomas (TNC). Clinical trials using anti-EGFR therapies are actually performed although no activating alterations (mutations, amplifications, or rearrangements) of EGFR have been clearly recognized in order to identify new targeted modalities for IBCs. We explored mammary-derived growth inhibitor (MDGI), estrogen-induced gene-121 (EIG121), and mitogen-induced gene-6 (MIG6), three posttranslational EGFR trafficking molecules implicated in EGFR spatiotemporal regulatory pathway. We quantified MDGI, EIG121, and MIG6 at mRNA levels by using real-time quantitative RT-PCR in a series of 440 IBCs and at protein levels by using immunohistochemistry in a series of 88 IBCs. Results obtained by RT-PCR showed that in IBCs, MDGI, MIG6, and EIG121 mRNA were mainly underexpressed (25.7%, 45.0%, and 16.1%, respectively) particularly in the TNC subtype for EIG121 (60.3%). We also observed mRNA overexpression of MDGI and EIG121, respectively, in 12.7% and 22.3% of IBCs. These altered mRNA expressions were confirmed at the protein level. Some links were found between expression patterns of these three genes and several classical pathological and clinical parameters. Only EIG121 was found to have a prognostic significance (p=0.0038). Altered expression of these three major EGFR posttranslational negative regulators could create an aberrant EGFR-mediated oncogenic signalling pathway in IBCs. MDGI, MIG6, and EIG121 expression status also may be potential useful biomarkers (sensitivity or resistance) in targeted EGFR therapy.

Relationship between tumor characteristics and HER2/neu overexpression with response and outcome in locally advanced breast cancer (LABC) patients (pts) treated with neoadjuvant anthracycline-based chemotherapy (CHT)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10698-10698
Author(s):  
A. J. Fernandez Sagarra ◽  
C. Alvarenga ◽  
M. Alvarenga ◽  
M. L. Kraft ◽  
L. C. Teixeira
Keyword(s):  
Prognostic Factors ◽  
Lymph Node ◽  
Residual Disease ◽  
Clinical Stage ◽  
Pathological Response ◽  
Lymph Node Status ◽  
Her2 Overexpression ◽  
Stage Iiia ◽  
Microscopic Residual Disease ◽  
Grade Iii

10698 Objectives: To retrospectively evaluate the relationship between HER2/neu status, pts’ characteristics, prognostic factors and clinical outcome in LABC women treated with neoadjuvant anthracycline-based CHT. Patients and Methods: 118 pts. with stage IIIA-B LABC, excluding inflammatory cancer, were included. HER2 overexpression was evaluated by immunohistochemistry (IHC), only IHC 3+ were defined as positive. The disease-free survival (DFS) was calculated according to Kaplan-Meier method. Fisher test, hazard ratios with 95% interval confidence, and Cox or Wilcoxon models were used. Kruskall-Wallis was used for comparison between medians. Results: Median age was 49 y (range: 31–69); 66 were pre-menopausal, 43 were stage IIIA and 77 IIIB; 59 pts. were N2. Primary tumor average size was 70 mm; 44 tumors were ER+, 43 PR+, 26 (22%) HER 3+, 104 histological grade III, 57 nuclear grade III. Seventy-four pts. (62.7%) achieved objective responses, with 7 complete clinical remissions. There was 1 progressive disease and only 3 pts. (2.5%) didn’t undertake mastectomy. After surgery, four pts. (3.5%) were evaluated as pathological complete remission, 6 (5.2%) with microscopic residual disease and 105 with macroscopic residual tumor. The median DFS was 19 months for the whole group and 39,6 and 31,6 for those achieving complete pathological remission and microscopic residual disease, respectively. There was no association between HER2/neu overexpression and pts’ characteristics, tumor prognostic factors nor with clinical or pathological responses. Negative PR, high tumor nuclear grade, clinical stage IIIA and complete clinical response were predictive factors for pathological response. In multivariate analysis, only pathological lymph node status was prognostic factor for DFS. Conclusions: There was no significant association between HER2 overexpression, tumor prognostic factors and clinical or pathological response to neoadjuvant CHT. Negative PR, high nuclear tumor grade, clinical stage IIIA and clinical complete response were associated to complete pathological response. Lymph node status was a strong prognostic factor for DFS. No significant financial relationships to disclose.

Clinical and pathological characteristics of basal -like breast carcinomas

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10768-10768
Author(s):  
F. Gago ◽  
D. R. Ciocca ◽  
B. Mendiondo ◽  
J. Orozco ◽  
O. Tello
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
P53 Protein ◽  
Premenopausal Women ◽  
Tumor Grade ◽  
Lymph Node Status ◽  
Control Group ◽  
Breast Carcinomas ◽  
Pathological Characteristics ◽  
Her 2

10768 Clinical and pathological characteristics of basal -like breast carcinomas. Background: Genetic studies have revealed different subtypes of breast carcinomas with particular molecular characteristics. Basal-like breast carcinomas are characterized by negative hormonal receptors and negative HER-2 receptor. We have compared basal-like breast carcinomas with a randomized control population selected from our data base of breast cancer. Methods: From 2127 breast invasive carcinomas, 716 were evaluated with immunohistochemical methods, considering the expression of estrogen receptors, progesterone receptor, HER-2 and p53 protein, between 1989 and 2005. According to the molecular classification the results were: 1) Luminal 398 (55.6%), 2) HER- 2 positive: 193 (26.9%) and 3) Basal-like 124 (17.5%). We retrospectively analyzed the age at diagnosis, menopausal status, tumor size, histological grade, histopathology, lymph node status, stage and the evolution of the breast cancer. The average follow-up was 66.2 months. The control group consisted of 170 patients. The statistical analysis was performed with chi-square test, Fisher’s test and the non parametric test of the Mac Nemar’s signs. Results: The median age at diagnosis was 52 years old. This is lower than the average age of the Tumor Register of Mendoza, that is 60 years (p: < 0.01). The basal-like carcinomas predominated in premenopausal women (p = 0.07), and had a higher proportion of high tumor grade (p ≤ 0.0001) and expression of p53 protein (p=0.01). There were not significant statistical differences concerning the tumor size, the lymph node status, histopathology, and the stage at presentation. The 5-year disease-free survival (DFS) of basal-like breast carcinomas was 71.7% and the 5-year overall survival (OS) was 83.3%. Whereas the DFS for the control group was 77.3% and the OS was 87.3%. Conclusions: The basal-like breast carcinomas are characterized by having a younger age at presentation, predominating in premenopausal women, and presenting a high tumor grade with overexpression of p53 protein. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document